Iomeprol is a pharmaceutical drug used as a radiocontrast agent in X-ray imaging. It is sold under the trade names Imeron and Iomeron.[1][2]
Clinical data | |
---|---|
Trade names | Imeron, Iomeron |
Routes of administration | Intravenous, by mouth |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | none |
Elimination half-life | 109±20 min |
Excretion | via kidneys |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C17H22I3N3O8 |
Molar mass | 777.089 g·mol−1 |
3D model (JSmol) |
|
| |
|
It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[1] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.[1]
The substance is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.[3]